Ensuring access and coverage remains a top priority
July 3, 2024 (WASHINGTON, D.C.) The Partnership to Fight Chronic Disease (PFCD) released the following statement in response to the U.S. Food and Drug Administration (FDA) traditional approval of KisunlaTM (donanemab), a therapy developed